Chardan Capital Predicts Prime Medicine FY2026 Earnings

Prime Medicine, Inc. (NYSE:PRME) – Investment analysts at Chardan Capital issued their FY2026 earnings per share (EPS) estimates for Prime Medicine in a report released on Monday, November 10th. Chardan Capital analyst G. Livshits anticipates that the company will post earnings per share of ($0.80) for the year. Chardan Capital currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($1.68) per share.

A number of other brokerages have also issued reports on PRME. Citigroup cut their price target on shares of Prime Medicine from $5.00 to $4.25 and set a “neutral” rating on the stock in a report on Tuesday. Wedbush restated an “outperform” rating and set a $8.00 target price on shares of Prime Medicine in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.21.

Prime Medicine Stock Performance

NYSE PRME traded down $0.06 during trading hours on Wednesday, hitting $3.86. The company had a trading volume of 98,275 shares, compared to its average volume of 2,828,527. Prime Medicine has a 52 week low of $1.11 and a 52 week high of $6.94. The firm has a 50 day simple moving average of $4.98 and a 200 day simple moving average of $3.49. The firm has a market capitalization of $519.05 million, a price-to-earnings ratio of -1.89 and a beta of 2.64.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PRME. Creative Planning acquired a new position in shares of Prime Medicine in the 2nd quarter valued at $25,000. Freedom Investment Management Inc. purchased a new stake in Prime Medicine during the 2nd quarter valued at about $26,000. R Squared Ltd purchased a new position in Prime Medicine in the 2nd quarter worth approximately $31,000. JTC Employer Solutions Trustee Ltd purchased a new stake in shares of Prime Medicine in the second quarter valued at approximately $33,000. Finally, Savant Capital LLC purchased a new position in Prime Medicine during the second quarter worth approximately $37,000. 70.37% of the stock is currently owned by hedge funds and other institutional investors.

About Prime Medicine

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.